Verrica Pharmaceuticals Stock Price, News & Analysis

Verrica Pharmaceuticals (VRCA) reported significant growth in YCANTH® dispensed applicator units for Q1 2025, reaching 10,102 units - a 16.7% sequential increase from Q4 2024's 8,654 units.

The company attributes this growth to their recent commercial restructuring and normalized distribution inventory levels. With stabilized channel inventory, the dispensed units are expected to more closely track demand and gross revenue going forward.

The management highlighted that strong market access, normalized inventory levels, and a focused commercial team building relationships within dermatology and pediatric communities position YCANTH® for sustainable revenue growth. The company aims to establish YCANTH® as the standard treatment for molluscum contagiosum.

Verrica Pharmaceuticals (Nasdaq: VRCA) has appointed Dr. Gavin Corcoran to its Board of Directors. Dr. Corcoran, currently Chief Development Officer at Formation Bio, brings extensive pharmaceutical experience from leadership positions at Sio Gene Therapies, Allergan, and Stiefel Laboratories.

The appointment comes at a important time as Verrica experiences growing commercial success with YCANTH®, its treatment for molluscum contagiosum, which is gaining increased adoption among dermatologists and pediatricians. The company aims to leverage Dr. Corcoran's expertise in developing innovative medicines and executing strategic transactions to advance its late-stage dermatology pipeline.

Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's President and CEO, Jayson Rieger, PhD, MBA, will engage in a fireside chat during the event.

The virtual presentation is scheduled for Tuesday, April 8, 2025, at 1:30 pm ET. Interested participants can access the live webcast through a provided link or via the Investors/Presentations & Events section on Verrica's website. The webcast recording will remain available for 90 days after the event, which runs from April 7-10, 2025.

Verrica Pharmaceuticals (Nasdaq: VRCA) has appointed Noah L. Rosenberg, M.D. as Chief Medical Officer. Dr. Rosenberg brings over 30 years of clinical and therapeutic development experience, with multiple global drug approvals including dermatology treatments.

Dr. Rosenberg succeeds Gary Goldenberg, who will continue as a strategic advisor after overseeing the FDA approval of YCANTH® for molluscum contagiosum treatment. In his new role, Rosenberg will focus on establishing YCANTH® as the standard care for molluscum contagiosum and advancing clinical programs in basal cell carcinoma and common warts.

As part of his appointment, Dr. Rosenberg received an inducement grant of stock options to purchase 325,000 shares at $0.5221 per share, vesting over four years with initial 1/8th vesting after six months.

Verrica Pharmaceuticals (VRCA) reported Q4 and full-year 2024 results, highlighting a 12.3% quarterly growth in YCANTH® dispensed applicator units to 8,654 in Q4'24. The company achieved positive quarterly revenue earlier than expected and implemented significant cost reductions, targeting cash-positive monthly operating results by end of 2025.

Q4 2024 financial results showed product revenue of $0.3M (down from $1.9M in Q4 2023), with reduced operating expenses. Full-year 2024 results included product revenue of $6.6M (up from $4.7M in 2023). The company reported a net loss of $76.6M for 2024.

Key developments include: a $42M public offering in November 2024, strengthening the balance sheet; advancement of late-stage pipeline programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH); and introduction of a new single applicator configuration in Q1 2025. The company ended 2024 with $46.3M in cash and cash equivalents.

Verrica Pharmaceuticals (Nasdaq: VRCA) has scheduled its Q4 and full-year 2024 financial results conference call and webcast for March 11, 2025, at 4:30 p.m. ET. The dermatology therapeutics company will present financial performance data and provide a corporate update during the event.

Participants can join via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) using conference ID: VERRICA. The webcast will be accessible through the company's investor relations website section, with a replay available for 90 days post-event.

Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston. Jayson Rieger, PhD, MBA, President and CEO, will engage in a fireside chat at the event.

The presentation is scheduled for Monday, March 3, 2025, at 2:30 pm ET in Boston, MA. Interested participants can access a live webcast through the provided link or via the Investors/Presentations & Events section on Verrica's website. The webcast recording will remain available for 90 days after the event.

Verrica Pharmaceuticals (NASDAQ: VRCA) presented three posters featuring clinical data from Part 2 of their Phase 2 study of VP-315, a novel oncolytic peptide for treating basal cell carcinoma (BCC), at the 2025 Winter Clinical Dermatology Conference. The study, involving 82 patients with 91 tumors, demonstrated a 97% Calculated Objective Response Rate.

Key findings include: 51% of tumors achieved complete histological clearance, while remaining patients showed an average 71% reduction in tumor size. The treatment showed favorable safety profiles with no Treatment Related Serious Adverse Events, and mostly mild to moderate adverse events.

The company plans to request an End-of-Phase 2 meeting with the FDA in first half of 2025, with genomic and T-cell data expected in Q1 2025. Verrica believes VP-315 could serve as a first-line therapy in both primary and neoadjuvant settings, potentially representing a multi-billion-dollar opportunity as a non-surgical alternative for BCC patients.

Verrica Pharmaceuticals (NASDAQ: VRCA) reports positive momentum in Q4 2024, with YCANTH dispensed applicator units surpassing the previous quarter's numbers despite cost reductions. The company notes significant reduction in distributor inventory levels and plans to launch a single applicator configuration in Q1 2025 to enhance accessibility and reduce costs for physician practices.

The company is expanding distribution through local independent pharmacies while implementing targeted cost management. The new single applicator packaging aims to facilitate initial purchases and increase patient access through buying groups, hospitals, and government entities. Verrica continues to advance its pipeline, including YCANTH for common warts in partnership with Torii Pharmaceutical, and VP-315, an oncolytic peptide showing promising Phase 2 results for basal cell carcinoma treatment.